IP Library Granted Patent US 9,051,602
Granted Patent B2
US 9,051,602 · App. 12/645,129 · Granted Jun 9, 2015

Methods and genotyping panels for detecting alleles, genomes, and transcriptomes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,051,602
App. No.
12/645,129
Granted
Jun 9, 2015
Kind
B2
Abstract

Disclosed are methods and genotyping panels for detecting alleles, genomes, and transcriptomes in admixtures of two individuals.

Claims (24)

1. A method of obtaining and analyzing a fetal genome from a mixture of maternal and fetal cells, comprising:

a) obtaining a maternal blood sample comprising a mixture of maternal and fetal cells;

b) enriching said sample from step a) for said fetal cells, wherein fetal cells in the mixture of maternal and fetal cells are enriched to between 1 in 100 and 1 in 100,000 fetal cells per maternal cells;

c) dividing said enriched sample from step b) into at least about 1,000 subsamples, wherein each subsample has an average of less than one cell;

d) performing whole genome amplification on each at least about 1,000 subsamples from step c) to provide an amplified product for each subsample, wherein each amplified product has an amplified genome from an average of about one cell, and wherein at least 99% of the amplified genomes in said amplified product are not from a fetal cell;

e) dividing each of said amplified product from step d) into aliquots, wherein each aliquot contains at least one copy of said amplified genome from said cell, and wherein at least 99% of the amplified genomes in said aliquots are not from a fetal cell;

f) screening or genotyping an aliquot from step e) for the presence of a fetal identifier, wherein said screening or genotyping comprises:

i) determining a maternal genotype and a fetal genotype at at least 1 SNP(s) per chromosome-specific SNP panel on at least 10 chromosome-specific panels;

ii) selecting as test loci from step i) at least 1 SNP(s) per chromosome-specific panel on at least 10 chromosome-specific panels where the maternal genotype is homozygous and the fetal genotype is heterozygous;

iii) screening or genotyping said aliquot from step e) for a genotype differing from a maternal genotype at at least one of said test loci from step ii), wherein the presence of said genotype differing from said maternal genotype indicates the possible presence of an informative paternal allele in said aliquot and thus said corresponding subsample;

iv) screening or genotyping an aliquot from a subsample having an informative paternal allele from step iii) for a genotype differing from a maternal genotype at at least 1 test loci per chromosome-specific panel on at least 10 chromosome-specific panels from step ii), wherein the presence of said genotype differing from said maternal genotype indicates the presence of an informative paternal allele in said aliquot,

g) identifying the presence of a fetal cell in at least one subsample from step c) whose aliquot contains an informative paternal allele from step f) iv); and

h) analyzing another aliquot from step e) from said at least one subsample from step g) identified as containing fetal cell to detect a genetic variation in said genome of said fetal cell.

2. The method of claim 1 , wherein said genetic variation is selected from the group consisting of a chromosomal rearrangement, a copy number variation, and a polymorphism.

3. The method of claim 1 , wherein said analyzing to detect a genetic variation comprises determining a ratio of maternally- and paternally-inherited alleles, wherein said ratio is analyzed to determine the presence of a genetic variation.

4. The method of claim 1 , wherein said analyzing to detect a genetic variation comprises determining a copy number of alleles in said aliquot, wherein said copy number of alleles is analyzed to determine the presence of a genetic variation.

5. The method of claim 1 , wherein said maternal genotype and fetal genotype are determined from a mixture of maternal and fetal nucleic acids from a mixture of cell-free nucleic acids.

6. The method of claim 5 , wherein the source of said maternal and fetal cell-free nucleic acid sample is blood, serum, plasma, urine, cervical swab, cervical lavage, uterine lavage, or culdocentesis from a pregnant female.

7. The method of claim 1 , further comprising pooling an aliquot from two or more subsamples prior to screening or genotyping an aliquot for the presence of a fetal identifier, wherein said screening or genotyping further comprises:

individually screening or genotyping a second aliquot from the subsamples whose pooled aliquots contained an informative paternal allele.

8. The method of claim 7 , wherein said pooling comprises the use of an indexed system of rows and columns of wells comprising said aliquots.

9. The method of claim 1 , wherein aliquots from two or more subsamples identified as containing a fetal cell are pooled prior to said analyzing another aliquot from said at least one subsample identified as containing fetal cell to detect a genetic variation in said fetal cell.

10. The method of claim 7 , wherein aliquots from two or more subsamples identified as containing a fetal cell are pooled prior to said analyzing another aliquot from said at least one subsample identified as containing fetal cell to detect a genetic variation in said fetal cell.

11. The method of claim 1 , wherein the loci used to determine the presence of an informative paternal allele is not the same loci used to detect a genetic variation.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2017
From: CELULA, INC.
To: PROGENITY, INC.
Reel/Frame 042087/0041 →
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2015
From: COMERICA BANK
To: CELULA, INC.
Reel/Frame 035291/0215 →
RELEASE OF SECURITY INTEREST Recorded Jan 16, 2014
From: ENTERPRISE PARTNERS VI, L.P.; THE SENYEI FAMILY TRUST; VERSANT VENTURE CAPITAL II, L.P.; VERSANT SIDE FUND II, L.P.; VERSANT AFFILIATES FUND II-A, L.P.; KAISER PERMANENTE VENTURES LLC - SERIES A; KAISER PERMANENTE VENTURES LLC - SERIES B; THE PERMANENTE FEDERATION LLC - SERIES I; THE PERMANENTE FEDERATION LLC - SERIES J
To: CELULA, INC.
Reel/Frame 031984/0625 →
AMENDMENT ADDING SECURED PARTY TO SECURITY AGREEMENT DATED 10/24/2011 AND RECORDED ON 11/10/2011 AT PATENT REEL/FRAME 027212/0703 Recorded Oct 7, 2013
From: CELULA, INC.
To: THE SENYEI FAMILY TRUST
Reel/Frame 031371/0303 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2012
From: SKYLINE VENTURE PARTNERS V, L.P.; CHL MEDICAL PARTNERS III, L.P.; CHL MEDICAL PARTNERS III SIDE FUND, L.P.
To: CELULA, INC.
Reel/Frame 028299/0612 →
SECURITY AGREEMENT Recorded Nov 10, 2011
From: CELULA, INC.
To: ENTERPRISE PARTNERS VI, L.P.; VERSANT VENTURE CAPITAL II, L.P.; VERSANT SIDE FUND II, L.P.; VERSANT AFFILIATES FUND II-A, L.P.; SKYLINE VENTURE PARTNERS V, L.P.; KAISER PERMANENTE VENTURES LLC - SERIES A; KAISER PERMANENTE VENTURES LLC - SERIES B; THE PERMANENTE FEDERATION LLC - SERIES I; CHI MEDICAL PARTNERS III, L.P.; CHI MEDICAL PARTNERS III SIDE FUND, L.P.
Reel/Frame 027212/0703 →
SECURITY AGREEMENT Recorded Oct 25, 2011
From: CELULA, INC.
To: COMERICA BANK
Reel/Frame 027114/0563 →